Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

Key Takeaways The AUSCO trial showed a 94% success rate in achieving significant continence improvement in men with SUI using the artificial urinary sphincter. The study found no device infections and ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

In a study presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2025 Winter Meeting in Rancho Mirage, California, investigators presented data on the β-3 agonist ...

At this year’s American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, the AUA released their new guideline on genitourinary syndrome of menopause in collaboration with the Society ...

Session ID: 2025-06-29:1a96e3213c8fbb3b6e53ba90 Player Element ID: vjs_video_3 ...

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

The minimally invasive incontinence treatment ProACT recently became available to patients of Allegheny Health Network (AHN) in Pittsburgh, Pennsylvania. In this interview, Kiran Sury, MD, describes ...

Key Takeaways Nadofaragene firadenovec achieved a 79% complete response rate in CIS patients at three months, with durable responses at six and nine months. Real-world safety data showed mostly ...